NasdaqCM - Nasdaq Real Time Price • USD
Cyclo Therapeutics, Inc. (CYTH)
As of 12:11 PM EDT. Market Open.
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Sep 2023) | Next Qtr. (Dec 2023) | Current Year (2023) | Next Year (2024) |
|---|---|---|---|---|
| No. of Analysts | -- | -- | -- | -- |
| Avg. Estimate | 0 | 0 | 0 | 0 |
| Low Estimate | 0 | 0 | 0 | 0 |
| High Estimate | 0 | 0 | 0 | 0 |
| Year Ago EPS | -0.5 | -0.59 | -- | -- |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Sep 2023) | Next Qtr. (Dec 2023) | Current Year (2023) | Next Year (2024) |
|---|---|---|---|---|
| No. of Analysts | 1 | 1 | 1 | 1 |
| Avg. Estimate | 495k | 311k | 1.08M | 2.15M |
| Low Estimate | 430k | 310k | 1.08M | 2.15M |
| High Estimate | 430k | 310k | 1.08M | 2.15M |
| Year Ago Sales | -- | 187k | 1.38M | 1.08M |
| Sales Growth (year/est) | -- | 66.30% | -21.80% | 99.80% |
Earnings History
| CURRENCY IN USD | 9/30/2022 | 12/31/2022 | 3/31/2023 | 6/30/2023 |
|---|---|---|---|---|
| EPS Est. | -0.53 | -0.25 | -0.42 | -0.44 |
| EPS Actual | -0.5 | -0.59 | -0.46 | -0.33 |
| Difference | 0.03 | -0.34 | -0.04 | 0.11 |
| Surprise % | 5.70% | -136.00% | -9.50% | 25.00% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Sep 2023) | Next Qtr. (Dec 2023) | Current Year (2023) | Next Year (2024) |
|---|---|---|---|---|
| Current Estimate | 0 | 0 | 0 | 0 |
| 7 Days Ago | -0.35 | -0.37 | -1.56 | -1.05 |
| 30 Days Ago | -0.35 | -0.37 | -1.56 | -1.05 |
| 60 Days Ago | -0.35 | -0.37 | -1.56 | -1.05 |
| 90 Days Ago | -0.35 | -0.37 | -1.56 | -1.05 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Sep 2023) | Next Qtr. (Dec 2023) | Current Year (2023) | Next Year (2024) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | -- | -- | -- | -- |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| CURRENCY IN USD | CYTH | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | -- | -- | -- | 0.80% |
| Next Qtr. | -- | -- | -- | 9.60% |
| Current Year | -- | -- | -- | 4.50% |
| Next Year | -- | -- | -- | 13.30% |
| Next 5 Years (per annum) | -- | -- | -- | 11.09% |
| Past 5 Years (per annum) | -- | -- | -- | -- |
Research Analysis
Analyst Price Targets
Fair Value
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Analyst Recommendations
- Strong Buy
- Buy
- Hold
- Underperform
- Sell
Earnings
Upgrades & Downgrades
| Upgrade | Maxim Group: Hold to Buy | 9/27/2023 |
| Downgrade | Maxim Group: Buy to Hold | 3/21/2023 |
| Initiated | Maxim Group: Buy | 12/17/2020 |
Related Tickers
DERM Journey Medical Corporation
3.4500
-3.63%
LSDI Lucy Scientific Discovery Inc.
1.1200
-8.94%
ASRT Assertio Holdings, Inc.
0.7751
+2.80%
PRFX PainReform Ltd.
0.8406
-5.10%
ORGO Organogenesis Holdings Inc.
2.8550
-0.17%
ESAIY Eisai Co., Ltd.
9.57
+2.55%
IXHL Incannex Healthcare Inc.
2.4100
+1.26%
QLI Qilian International Holding Group Limited
0.8201
+3.16%
ETON Eton Pharmaceuticals, Inc.
3.0950
+1.14%
VIVXF Avivagen Inc.
0.0064
0.00%